D47.1: Chronic myeloproliferative disease

D47.1, chronic myeloproliferative disease, is listed as a covered diagnosis in 7 Medicare billing and coding articles that apply to 38 HCPCS Level II codes, including J0881 (Injection, darbepoetin alfa, 1 microgram (non-esrd use)), J0885 (Injection, epoetin alfa, (for non-esrd use), 1000 units), Q5106 (Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for…). The articles come from 4 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with D47.1 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
J0881Injection, darbepoetin alfa, 1 microgram (non-esrd use)Special coverage instructions apply—4
J0885Injection, epoetin alfa, (for non-esrd use), 1000 unitsSpecial coverage instructions apply—4
Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 unitsSpecial coverage instructions apply—4
J0882Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)Special coverage instructions apply—4
Q5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 unitsSpecial coverage instructions apply—4
J0890Injection, peginesatide, 0.1 mg (for esrd on dialysis)Carrier judgment—4
Q4081Injection, epoetin alfa, 100 units (for esrd on dialysis)Special coverage instructions apply—4
J0888Injection, epoetin beta, 1 microgram, (for non esrd use)Special coverage instructions apply—3
J0887Injection, epoetin beta, 1 microgram, (for esrd on dialysis)Special coverage instructions apply—3
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodSpecial coverage instructions apply—2
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodSpecial coverage instructions apply—2
J9312Injection, rituximab, 10 mgSpecial coverage instructions apply—1
Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mgCarrier judgment—1
Q5119Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mgCarrier judgment—1
Q5115Injection, rituximab-abbs, biosimilar, (truxima), 10 mgSpecial coverage instructions apply—1
J8999Prescription drug, oral, chemotherapeutic, nosSpecial coverage instructions apply—1
J8530Cyclophosphamide; oral, 25 mgSpecial coverage instructions apply—1
J8597Antiemetic drug, oral, not otherwise specifiedSpecial coverage instructions apply—1
J8610Methotrexate; oral, 2.5 mgSpecial coverage instructions apply—1
J8498Antiemetic drug, rectal/suppository, not otherwise specifiedSpecial coverage instructions apply—1
Q0162Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenSpecial coverage instructions apply—1
J8540Dexamethasone, oral, 0.25 mgSpecial coverage instructions apply—1
Q0166Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimenSpecial coverage instructions apply—1
J8501Aprepitant, oral, 5 mgSpecial coverage instructions apply—1
Q0164Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenSpecial coverage instructions apply—1

13 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing D47.1

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other D47 diagnoses (Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue)

Frequently asked questions

Does Medicare cover D47.1 (Chronic myeloproliferative disease)?

Medicare covers items and services, not diagnoses. 7 Medicare billing and coding articles list D47.1 as a covered diagnosis for 38 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 D47.1?

The Level II codes from the policies most specific to this diagnosis are J0881 (Injection, darbepoetin alfa, 1 microgram (non-esrd use), 4 articles); J0885 (Injection, epoetin alfa, (for non-esrd use), 1000 units, 4 articles); Q5106 (Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for…, 4 articles); J0882 (Injection, darbepoetin alfa, 1 microgram (for esrd on…, 4 articles); Q5105 (Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for…, 4 articles). Code choice depends on the item supplied; check each code's descriptor.

Which Medicare policy articles list D47.1?

A56795 (Billing and Coding: Erythropoiesis Stimulating Agents (ESAs)); A59101 (Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars); A58982 (Billing and Coding: Erythropoiesis Stimulating Agents), and 4 more articles.

What is ICD-10-CM code D47.1?

D47.1 is the ICD-10-CM code for chronic myeloproliferative disease, in category D47 (Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup